Professional Documents
Culture Documents
PERTUSSIS &
TETANUS
Dr Sarika Gupta, Asst. Professor
INTRODUCTION
INTRODUCTION
EPIDEMIOLOGY
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
CLINICAL MANIFESTATIONS
1.
2.
3.
4.
5.
6.
Enzyme immunossay
PCR for A or B portion of the toxic gene tox
Hypoglycemia, glycosuria, BUN, or abnormal ECG for liver,
kidney and heart involvement
Differential diagnosis:
Common cold
Congenital syphilis snuffle
Sinusitis
Adenoiditis and foreign body in nose
Streptococcal pharyngitis
Infectious mononucleosis
COMPLICATIONS
1.
2.
3.
Toxic Neuropathy:
TREATMENT
1.
Antitoxin:
Mainstay of therapy
Antitoxin is administered as a single empirical dose of 20,000120,000 U based on the degree of toxicity, site and size of the
membrane, and duration of illness
2.
Antimicrobial therapy
PREVENTION
Asymptomatic Case Contacts:
Asymptomatic Carriers:
VACCINE
INTRODUCTION
EPIDEMIOLOGY
ETIOLOGY
PATHOGENESIS
CLINICAL MANIFESTATIONS
CLINICAL MANIFESTATIONS
Cough increase for next 2-3 weeks and decreases over next 10
weeks
Absence of whoop and/or post-tussive vomiting does not rule
out clinical diagnosis of pertussis
paroxysmal cough>2 weeks with or without whoop and/or
post-tussive vomiting is the hallmark feature of pertussis
Stage III (convalecence stage): period of gradual recovery
even up to 6 months
COMPLICATIONS
1.
2.
3.
DIAGNOSIS
1.
2.
3.
DIAGNOSIS
4.
5.
TREATMENT
1.
2.
3.
PREVENTION
LOCKJAW
Tetanus
INTRODUCTION
EPIDEMIOLOGY
PATHOGENESIS
PREDISPOSING FACTORS
CLINICAL MANIFESTATIONS
CLINICAL MANIFESTATIONS
TREATMENT
1.
2.
TREATMENT
3.
4.
5.
PREVENTION
PREVENTION
VACCINE:
DPT vaccine: 3 primary doses starting at 6 weeks of age
1st booster at 16-18 months of age, 2nd booster at 5 years of
age
At 10 years of age Tdap/Td followed by Td every 10 years
Catch-up vaccination:
Below 7 years: DPT at 0,1 and 6 months